Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014;37(1):202-9.
doi: 10.2337/dc13-0410. Epub 2013 Sep 11.

Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications

Rochelle N Naylor  1 , Priya M John, Aaron N Winn, David Carmody, Siri Atma W Greeley, Louis H Philipson, Graeme I Bell, Elbert S Huang
Affiliations
Comparative Study

Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications

Rochelle N Naylor et al. Diabetes Care. 2014.

Abstract

OBJECTIVE To evaluate the cost-effectiveness of a genetic testing policy for HNF1A-, HNF4A-, and GCK-MODY in a hypothetical cohort of type 2 diabetic patients 25-40 years old with a MODY prevalence of 2%. RESEARCH DESIGN AND METHODS We used a simulation model of type 2 diabetes complications based on UK Prospective Diabetes Study data, modified to account for the natural history of disease by genetic subtype to compare a policy of genetic testing at diabetes diagnosis versus a policy of no testing. Under the screening policy, successful sulfonylurea treatment of HNF1A-MODY and HNF4A-MODY was modeled to produce a glycosylated hemoglobin reduction of -1.5% compared with usual care. GCK-MODY received no therapy. Main outcome measures were costs and quality-adjusted life years (QALYs) based on lifetime risk of complications and treatments, expressed as the incremental cost-effectiveness ratio (ICER) (USD/QALY). RESULTS The testing policy yielded an average gain of 0.012 QALYs and resulted in an ICER of 205,000 USD. Sensitivity analysis showed that if the MODY prevalence was 6%, the ICER would be ~50,000 USD. If MODY prevalence was >30%, the testing policy was cost saving. Reducing genetic testing costs to 700 USD also resulted in an ICER of ~50,000 USD. CONCLUSIONS Our simulated model suggests that a policy of testing for MODY in selected populations is cost-effective for the U.S. based on contemporary ICER thresholds. Higher prevalence of MODY in the tested population or decreased testing costs would enhance cost-effectiveness. Our results make a compelling argument for routine coverage of genetic testing in patients with high clinical suspicion of MODY.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Policy decision for genetic testing for MODY due to mutations in HNF1A, HNF4A, and GCK. Yr, years.
Figure 2
Figure 2
A: Simulation model for complications for type 2 and HNF1A- and HNF4A-MODY. B: Simulation model for complications for GCK-MODY.
Figure 3
Figure 3
Sensitivity analyses for lifetime ICER. SU, sulfonylurea.
See this image and copyright information in PMC

References

    1. Frayling TM, Evans JC, Bulman MP, et al. beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors. Diabetes 2001;50(Suppl. 1):S94–S100 - PubMed
    1. Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes 1975;24:44–53 - PubMed
    1. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010;53:2504–2508 - PubMed
    1. Shepherd M, Pearson ER, Houghton J, Salt G, Ellard S, Hattersley AT. No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care 2003;26:3191–3192 - PubMed
    1. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003;362:1275–1281 - PubMed

Publication types

MeSH terms

Substances